Author

G. Massacci

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

C. Fuoco· 2 shared D. Mougiakakos· 2 shared F. Riccio· 2 shared F. Sacco· 2 shared G. Cesareni· 2 shared G. Giuliani· 2 shared G. M. Pugliese· 2 shared L. Castagnoli· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. Fuoco

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

S. Latini, V. Venafra, G. Massacci, V. Bica, S. Graziosi, G. M. Pugliese, M. Iannuccelli, F. Frioni, G. Minnella, J. D. Marra, P. Chiusolo, G. Pepe, M. Helmer-Citterich, D. Mougiakakos, M. Boettcher, , F. Sacco

This study develops a systems-based strategy to predict drug sensitivity in FLT3-ITD AML by integrating genomic, transcriptomic data with a prior-knowledge signaling network.

bioRxiv · Jun 22, 2023Cancer Biology

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

G. Massacci, V. Venafra, S. Latini, V. Bica, G. M. Pugliese, F. Klingelhuber, N. Krahmer, T. Fischer, D. Mougiakakos, M. Boettcher, L. Perfetto, F. Sacco

The paper identifies the WEE1-CDK1 axis as a key driver of TKI resistance in FLT3-ITD positive AML and suggests combination therapy as a potential treatment.

bioRxiv · May 16, 2022Cancer Biology

Transcription Factor Activation Profiles (TFAP) identify compounds promoting differentiation of Acute Myeloid Leukemia cell lines

F. Riccio, E. Micarelli, R. Secci, G. Giuliani, S. Vumbaca, G. Massacci, L. Castagnoli, C. Fuoco, G. Cesareni

This paper identifies compounds that promote differentiation of AML cell lines by analyzing transcription factor activation profiles from existing drug data.

bioRxiv · Jun 22, 2021Cell Biology

SCA-1 micro-heterogeneity in the fate decision of dystrophic fibro/adipogenic progenitors

G. Giuliani, S. Vumbaca, C. Fuoco, C. Gargioli, E. Giorda, G. Massacci, A. Palma, A. Reggio, F. Riccio, M. Vinci, L. Castagnoli, G. Cesareni

The paper investigates micro-heterogeneity in dystrophic fibro/adipogenic progenitors (FAPs) using SCA-1 expression levels and shows differential adipogenic and fibrogenic responses between two FAP states.

bioRxiv · May 14, 2020Cell Biology